Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of inhaled cromolyn (ALZT-OP1a) for post-stroke cognitive impairment
MOH_2017-04-03_000293Phase 2Not yet recruiting
- Sponsor
- AZTherapies
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sodium cromoglycate in post-stroke cognitive impairment (PSCI) (2 arms), sponsored by AZTherapies. Planned start Dec 2016; status: not yet recruiting.
02
Drugs
sodium cromoglycate
03
Conditions
post-stroke cognitive impairment (PSCI)
Beyond the preview
Go deeper on MOH_2017-04-03_000293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-04-03_000293.